share_log

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.2%),The Tiger Cub Trust(30.3%)

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.2%),The Tiger Cub Trust(30.3%)

Mangoceuticals | SC 13D/A：超過5%持股股東披露文件(修正)-Jacob D. Cohen(34.2%),The Tiger Cub Trust(30.3%)
美股SEC公告 ·  08/28 07:50
牛牛AI助理已提取核心訊息
On August 27, 2024, Mangoceuticals, Inc. experienced a significant change in its shareholder structure, as detailed in the latest Schedule 13D/A filing with the United States Securities and Exchange Commission. Jacob D. Cohen, a major shareholder, reported a transfer of 800,000 shares of common stock to The Tiger Cub Trust, an entity he controls, without any consideration. This amendment, identified as Amendment No. 3, supplements previous filings made on May 3, 2023, January 2, 2024, and June 5, 2024. Following this gifting of shares, Jacob D. Cohen and The Tiger Cub Trust collectively hold an aggregate of 10,825,000 shares, representing 34.2% of the company's issued common stock. The Tiger Cub Trust alone holds 9,075,000 shares, accounting for 30.3% of the common stock. The filing also notes that Cohen has sole voting and dispositive power over 1,750,000 shares, which includes shares issuable upon the exercise of vested options. The total number of common shares outstanding as confirmed by Mangoceuticals' transfer agent is 29,905,803.
On August 27, 2024, Mangoceuticals, Inc. experienced a significant change in its shareholder structure, as detailed in the latest Schedule 13D/A filing with the United States Securities and Exchange Commission. Jacob D. Cohen, a major shareholder, reported a transfer of 800,000 shares of common stock to The Tiger Cub Trust, an entity he controls, without any consideration. This amendment, identified as Amendment No. 3, supplements previous filings made on May 3, 2023, January 2, 2024, and June 5, 2024. Following this gifting of shares, Jacob D. Cohen and The Tiger Cub Trust collectively hold an aggregate of 10,825,000 shares, representing 34.2% of the company's issued common stock. The Tiger Cub Trust alone holds 9,075,000 shares, accounting for 30.3% of the common stock. The filing also notes that Cohen has sole voting and dispositive power over 1,750,000 shares, which includes shares issuable upon the exercise of vested options. The total number of common shares outstanding as confirmed by Mangoceuticals' transfer agent is 29,905,803.
2024年8月27日，Mangoceuticals，Inc.的股東結構發生了重大變化，詳細信息在最新提交給美國證券交易委員會的13D/A表中。作爲主要股東的Jacob D. Cohen報告將80萬股普通股轉讓給他控制的實體The Tiger Cub Trust，且未獲任何對價。這份被稱爲Amendment No. 3的修正文書對此前提交的2023年5月3日、2024年1月2日和2024年6月5日的文書進行了補充。在這次股份禮物之後，Jacob D. Cohen和The Tiger Cub Trust共同持有1082.5萬股，佔公司已發行普通股的34.2%。The Tiger Cub Trust單獨持有907.5萬股，佔普通股的30.3%。文件還指出Cohen對175萬股擁有獨立的表決權和處分權，其中包括可行使的期權股。據Mangoceuticals的過戶代理所證實，已發行的普通股總數爲29905083股。
2024年8月27日，Mangoceuticals，Inc.的股東結構發生了重大變化，詳細信息在最新提交給美國證券交易委員會的13D/A表中。作爲主要股東的Jacob D. Cohen報告將80萬股普通股轉讓給他控制的實體The Tiger Cub Trust，且未獲任何對價。這份被稱爲Amendment No. 3的修正文書對此前提交的2023年5月3日、2024年1月2日和2024年6月5日的文書進行了補充。在這次股份禮物之後，Jacob D. Cohen和The Tiger Cub Trust共同持有1082.5萬股，佔公司已發行普通股的34.2%。The Tiger Cub Trust單獨持有907.5萬股，佔普通股的30.3%。文件還指出Cohen對175萬股擁有獨立的表決權和處分權，其中包括可行使的期權股。據Mangoceuticals的過戶代理所證實，已發行的普通股總數爲29905083股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。